单位:[1]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Urol,Wuhan,Hubei,Peoples R China外科学系华中科技大学同济医学院附属同济医院泌尿外科[2]Huazhong Univ Sci & Technol,Inst Gerontol,Tongji Med Coll,Dept Geriatr,Tongji Hosp,Wuhan,Peoples R China综合医疗科华中科技大学同济医学院附属同济医院[3]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Reprod Med Ctr,Wuhan,Hubei,Peoples R China妇产科学系计划生育专科华中科技大学同济医学院附属同济医院[4]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Endocrinol,Wuhan,Peoples R China内科学系内分泌内科华中科技大学同济医学院附属同济医院
Phosphodiesterase-5 inhibitors (PDE5-i) have been widely used in clinical practice for the treatment of erectile dysfunction (ED). However, due to its suboptimal therapeutic effects and side effects, it is necessary to develop new medicines for ED treatment. Botanical drugs have been widely investigated as potential ED treatment drugs and have shown promising therapeutic effects. This review summarized 34 studies, including five botanical drugs with PDE5 inhibitory activity, seven botanical drugs without PDE5 inhibitory activity, and six mixed botanical drugs. The results of clinical studies regarding the aforementioned botanical drugs and relevant mechanisms are summarized in this study. It is necessary to conduct high-quality clinical trials to verify the dosage, targeted patients and therapeutic effects, and further pharmacology experiments are also needed to identify the active compounds.